Tildrakizumab After IL-17 Failure - EMJ

This site is intended for healthcare professionals

Tildrakizumab After Anti-IL-17 Failure Improves Psoriasis Outcomes

Author:
Woman holding elbow up.

Key Summary:

  • Tildrakizumab after anti-IL-17 failure improved psoriasis outcomes over 52 weeks.
  • PASI90 was achieved by 66.7% of patients at week 52.
  • Dose escalation to 200 mg occurred frequently during follow-up.

TILDRAKIZUMAB, an interleukin 23 (IL-23) inhibitor, produced sustained clinical and patient-reported improvements in moderate-to-severe plaque psoriasis after anti-IL-17 treatment failure over 52 weeks, according to prospective real-world data from 30 patients.

The study evaluated patients who had failed treatment with a single interleukin 17 (IL-17) inhibitor before switching to tildrakizumab. Clinical outcomes were assessed using the Psoriasis Area and Severity Index (PASI) and Physician Global Assessment, alongside patient-reported measures of quality of life, wellbeing and treatment satisfaction.

Mean PASI scores fell from 12.2 at baseline to 1.1 at week 52, indicating substantial improvement in psoriasis severity during follow-up.

How Effective Was Tildrakizumab at Week 52?

At week 52, 88.9% of patients achieved at least 75% improvement in PASI score (PASI75), while 66.7% achieved PASI90 and 50% achieved PASI100. A total of 94.4% of patients reached a PASI score of 3 or lower.

Patient-reported outcomes also improved during treatment. Dermatology Life Quality Index (DLQI) and World Health Organization-Five Well-Being Index (WHO-5) scores showed significant improvements, while treatment satisfaction remained high.

The findings therefore indicated benefits across both clinician-assessed disease severity and patient-reported outcomes following the switch from an IL-17 inhibitor to tildrakizumab.

Why Was Tildrakizumab Dose Escalated?

Dose escalation was frequently observed during follow-up. Although 46.7% of patients initially received tildrakizumab 100 mg, all patients were subsequently escalated to 200 mg, with no patients remaining on the lower dose throughout follow-up.

The researchers noted that the study did not include a comparator group maintained on 100 mg. Consequently, the data could not establish whether the 200 mg regimen was comparatively more effective than continued treatment at 100 mg.

The findings nevertheless suggested that switching to tildrakizumab could provide sustained clinical and patient-reported benefits for patients with moderate-to-severe plaque psoriasis following IL-17 inhibitor failure. The study also highlighted frequent escalation to the 200 mg dose during 52 weeks of real-world follow-up.

Reference

Di Brizzi EV et al. Switching to tildrakizumab 200 mg after anti-il-17 failure in moderate-to-severe psoriasis: a 52-week prospective real-world study. Dermatol Ther (Heidelb). 2026;DOI:10.1007/s13555-026-01973-x.

 

 

Featured image: triocean on Adobe Stock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.